NTRA

Natera Inc

Add to Watchlist

Advanced Chart

138.900

-2.165(-1.535%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

143.360

Open

142.050

VWAP

140.13

Vol

1.20M

Mkt Cap

18.97B

Low

138.240

Amount

168.60M

EV/EBITDA(TTM)

Total Shares

122.80M

18.06B

EV/OCF(TTM)

117.92

P/S(TTM)

9.73

Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

519.40M

+9.1%

500.51M

+13.81%

476.77M

+15.34%

Estimates Revision

The market is revising Upward the revenue expectations for Natera, Inc. (NTRA) for FY2025, with the revenue forecasts being adjusted by 3.69% over the past three months. During the same period, the stock price has changed by -9.21%.

Revenue Estimates for FY2025

Revise Upward

+3.69%

In Past 3 Month

Stock Price

Go Down

-9.21%

In Past 3 Month

11 Analyst Rating

48.60% Upside

Wall Street analysts forecast NTRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NTRA is 206.40 USD with a low forecast of 185.00 USD and a high forecast of 251.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

0 Hold

0 Sell

Strong Buy

48.60% Upside

Current: 138.900

Low

185.00

Averages

206.40

High

251.00

48.60% Upside

Current: 138.900

Low

185.00

Averages

206.40

High

251.00

Piper Sandler

Overweight

maintain

$205 -> $210

2025-05-15

Reason

Piper Sandler

Price Target

$205 -> $210

2025-05-15

maintain

Overweight

Reason

Piper Sandler raised the firm's price target on Natera to $210 from $205 following quarterly results. The firm keeps an Overweight rating on the shares.

Barclays

NULL -> Overweight

upgrade

$160 -> $190

2025-05-09

Reason

Barclays

Price Target

$160 -> $190

2025-05-09

upgrade

NULL -> Overweight

Reason

Barclays raised the firm's price target on Natera to $190 from $160 and keeps an Overweight rating on the shares. The firm updated the company's model post the earnings report.

BTIG

Buy

maintain

$190 -> $195

2025-05-09

Reason

BTIG

Price Target

$190 -> $195

2025-05-09

maintain

Buy

Reason

BTIG raised the firm's price target on Natera to $195 from $190 and keeps a Buy rating on the shares. The company delivered a strong Q1 earnings beat and raise, and Q1 was highlighted by record unit growth on a sequential basis in its Signatera MRD business, the analyst tells investors in a research note. Natera's drivers - robust volume growth across products, opportunities for average selling price expansion, new test offerings, and significant upside potential from updated guideline bodies - remain intact, the firm adds.

UBS

Dan Leonard

Buy

maintain

$211 -> $218

2025-05-09

Reason

UBS

Dan Leonard

Price Target

$211 -> $218

2025-05-09

maintain

Buy

Reason

UBS analyst Dan Leonard raised the firm's price target on Natera to $218 from $211 and keeps a Buy rating on the shares.

TD Cowen

Dan Brennan

Buy

maintain

$195 -> $200

2025-05-09

Reason

TD Cowen

Dan Brennan

Price Target

$195 -> $200

2025-05-09

maintain

Buy

Reason

Barclays

Luke Sergott

Buy

Maintains

$200 → $160

2025-04-10

Reason

Barclays

Luke Sergott

Price Target

$200 → $160

2025-04-10

Maintains

Buy

Reason

Barclays lowered the firm's price target on Natera to $160 from $200 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Natera Inc (NTRA.O) is -65.04, compared to its 5-year average forward P/E of -32.31. For a more detailed relative valuation and DCF analysis to assess Natera Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-32.31

Current PE

-65.04

Overvalued PE

-5.01

Undervalued PE

-59.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-33.13

Current EV/EBITDA

-67.56

Overvalued EV/EBITDA

-4.57

Undervalued EV/EBITDA

-61.68

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

9.25

Current PS

9.22

Overvalued PS

13.50

Undervalued PS

5.00

Financials

Annual

Quarterly

FY2025Q1

YoY :

+36.46%

501.83M

Total Revenue

FY2025Q1

YoY :

+6.54%

-79.18M

Operating Profit

FY2025Q1

YoY :

-0.98%

-66.94M

Net Income after Tax

FY2025Q1

YoY :

-10.71%

-0.50

EPS - Diluted

FY2025Q1

YoY :

-694.30%

22.64M

Free Cash Flow

FY2025Q1

YoY :

+11.28%

63.12

Gross Profit Margin - %

FY2025Q1

YoY :

-128.46%

4.65

FCF Margin - %

FY2025Q1

YoY :

-27.42%

-13.34

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

22.3M

USD

3-6

Months

42.6M

USD

6-9

Months

97.0M

USD

0-12

Months

10.2M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 265.72% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.4M

Volume

6-9

Months

1.6M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.0M

Volume

Months

6-9

278.8K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

8.0K

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

22.3M

USD

3-6

Months

42.6M

USD

6-9

Months

97.0M

USD

0-12

Months

10.2M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

NTRA News & Events

Events Timeline

2025-07-07 (ET)

2025-07-07

07:19:06

Natera presents data from Latitude MRD assay study at ESMO Congress

2025-06-04 (ET)

2025-06-04

07:32:49

Natera announces Medicare coverage for Signatera MRD assay

2025-05-08 (ET)

2025-05-08

16:46:44

Natera raises FY25 revenue view to $1.94B-$2.02B, consensus $1.92B

News

5.0

07-23NASDAQ.COM

Insider Sale: SEC. AND CHIEF LEGAL OFFICER of $NTRA Sells 10,000 Shares

2.0

07-20Benzinga

Schlumberger, Stellantis And ASML Holding Are Among Top 10 Large Cap Losers Last Week (July 14-July 18): Are The Others In Your Portfolio?

2.0

07-15NASDAQ.COM

Notable Two Hundred Day Moving Average Cross - NTRA

People Also Watch

CBOE

Cboe Global Markets Inc

Check Point Software Technologies Ltd

FAQ

What is Natera Inc (NTRA) stock price today?

The current price of NTRA is 138.9 USD — it has decreased -1.53 % in the last trading day.

NTRA

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

NTRA News & Events

Events Timeline

News

People Also Watch

FAQ

What is Natera Inc (NTRA) stock price today?

What is Natera Inc (NTRA)'s business?

What is the price predicton of NTRA Stock?

What is Natera Inc (NTRA)'s revenue for the last quarter?

What is Natera Inc (NTRA)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Natera Inc (NTRA)'s fundamentals?

How many employees does Natera Inc (NTRA). have?

What is Natera Inc (NTRA) market cap?